zinc finger protein 112Genealiases: ZFP112 · ZNF228
Q-omics provides the consensus-scored ZNF112 profile across patient tissues and cancer cell-line models. ZNF112 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF112 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF112 RNA expression shows 20,305 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where ZNF112 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF112 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF112 survival associations across molecular data types. ZNF112 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF112 RNA expression–survival associations across cancer types. High ZNF112 expression shows unfavorable associations in LGG, MESO, CESC and LUSC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF112 RNA expression.
This table summarizes ZNF112 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF112. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF112 shows lower tumor expression in THCA and UCEC and higher tumor expression in LIHC, CHOL, BLCA and HNSC. The THCA box plot shows higher ZNF112 RNA expression in normal versus tumor tissue (log2 FC = −0.905, t-test p < 0.001).
This table shows molecular features associated with ZNF112 in patient tissues and cancer cell lines. In patient samples, ZNF112 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF112 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
